Xiaoyi Chen
7 Papers
Xiaoyi Chen is an academic researcher. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has co-authored 6 publications.
Chat about Author
Papers
Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial
Beth Gordon,Lindsay Fogel,Gaurav Varma,Mateo Mejia Saldarriaga,Jaeil Ahn,Adolfo Aleman,Jessica Caro,Xiaoyi Chen,Jorge Monge,Harsh Parmar,David Kaminetzky,T. Moskovits,David S. Siegel,Gareth J. Morgan,Ruben Niesvizky,Noa Biran,Faith E. Davies +16 more
TL;DR: The MajesTEC-1 trial demonstrated promising clinical activity of teclistamab (Tec), a BCMAxCD3 bispecific antibody, with an overall response rate (ORR), and the presence of high-risk cytogenetics or EMD were not associated with ORR or depth of response.
3
Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
Eileen M Boyle,Patrick Blaney,James H. Stoeckle,Yubao Wang,Hussein Ghamlouch,Avital Tenenbaum,Ariel Siegel,Xiaoyi Chen,Gaurav Varma,David Kaminetzsky,Marc Braunstein,Lydia Montes,Jill Corre,Even H Rustad,Ola Landgren,Francesco Lauria,Benedetto Bruno,Aristotelis Tsirigos,Brian A Walker,Faith E. Davies,Dylan Gagler,Gareth J. Morgan +21 more
TL;DR: In this paper , the structural changes seen at the 1q level and integrated with expression and clinical data to identify potential drivers and gain insight into progression mechanisms were analyzed using GISTIC 2.0 and PFC.
1
Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
Eileen M Boyle,Francesco Lauria,David C. Coffey,Kylee H Maclachlan,Benjamin Diamond,Hussein Ghamlouch,Dylan Gagler,Patrick Blaney,Bachisio Ziccheddu,Yubao Wang,Emily Guzman,Avital Tenenbaum,Ariel Siegel,Xiaoyi Chen,Gaurav Varma,James E. Hoffman,Dickran Kazandjian,Hani Hassoun,Sham Mailankody,Urvi A Shah,Carlyn Rose C. Tan,Malin Hultcrantz,Michael Scordo,Gunjan L. Shah,Heather Landau,David J. Chung,Sergio Giralt,Yanming Zhang,Ahmet Dogan,Alexander M. Lesokhin,Dennis Verducci,Faith E. Davies,Saad Usmani,Neha Korde,Ola Landgren,Gareth J. Morgan +35 more
TL;DR: In this article , the authors integrated whole genome sequencing (WGS) and single cell RNA (scRNA), surface protein (CITE), and TCR sequencing from patients with NDMM to characterize genomic and immune microenvironment features related to the failure to achieve sustained remission.
Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer
Yan Zhang,Xiaoyi Chen,Huamin Wang,Shanisha Gordon-Mitchell,Srabani Sahu,Tushar D. Bhagat,Gaurav Choudhary,Srinivas Aluri,Kith Pradhan,Plabani Sahu,Milagros Carbajal,Hui Zhang,Beamon Agarwal,Aditi Shastri,R. Martell,Daniel T. Starczynowski,Ulrich Steidl,Anirban Maitra,Amit Verma +18 more
Maximising response depth is important in multiple myeloma.
Xiaoyi Chen,Faith E. Davies +1 more
TL;DR: In this paper , Goldschmidt et al. explored the addition of an anti-CD38 monoclonal antibody isatuximab to standard induction therapy with lenalidomide, bortezomib, and dexamethasone in transplantation eligible patients with newly diagnosed multiple myeloma.